Lake Street Capital Issues Positive Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price

LeMaitre Vascular (NASDAQ:LMAT) had its price target upped by investment analysts at Lake Street Capital from $105.00 to $110.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Lake Street Capital’s price target suggests a potential upside of 19.86% from the company’s current price.

LMAT has been the topic of a number of other reports. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Down 8.1 %

LMAT traded down $8.13 during trading on Friday, hitting $91.78. The company’s stock had a trading volume of 150,356 shares, compared to its average volume of 137,160. LeMaitre Vascular has a twelve month low of $62.39 and a twelve month high of $109.58. The stock’s fifty day moving average price is $96.90 and its 200-day moving average price is $94.66. The firm has a market capitalization of $2.06 billion, a P/E ratio of 50.54, a PEG ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Equities research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning grew its position in shares of LeMaitre Vascular by 20.7% in the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 617 shares during the last quarter. Raymond James & Associates boosted its position in shares of LeMaitre Vascular by 2.6% during the third quarter. Raymond James & Associates now owns 29,592 shares of the medical instruments supplier’s stock valued at $2,749,000 after purchasing an additional 748 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in shares of LeMaitre Vascular by 15.7% during the third quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock valued at $24,273,000 after purchasing an additional 35,383 shares in the last quarter. Oak Ridge Investments LLC bought a new stake in shares of LeMaitre Vascular during the third quarter valued at approximately $2,020,000. Finally, Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.